• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Fairooz F. Kabbinavar, Herbert I. Hurwitz, +5 authors Emily K Bergsland
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2003
  • PURPOSE This phase II trial investigated the safety and efficacy of two doses of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, plus fluorouracil (FU)/leucovorin (LV)Expand
  • Howard A. Iii Burris, Herbert I. Hurwitz, +13 authors Neil L. Spector
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2005 (First Publication: 10 August 2005)
  • PURPOSE This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with lapatinib (GW572016) in patients with ErbB1-expressing and/orExpand
  • Herbert I. Hurwitz, Louis Fehrenbacher, +6 authors Fairooz F. Kabbinavar
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2005 (First Publication: 20 May 2005)
  • PURPOSE In a phase III trial, combining bevacizumab (BV)--a recombinant, humanized, monoclonal antibody targeting vascular endothelial growth factor--with irinotecan, bolus fluorouracil (FU), andExpand
  • Hedy Lee Kindler, Donna Niedzwiecki, +12 authors Richard M Goldberg
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2010 (First Publication: 1 August 2010)
  • PURPOSE The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a multicenter phase II trial in patients with metastatic pancreatic cancer.Expand
  • Scott N. Holden, Stephan Eckhardt, +7 authors Herbert I. Hurwitz
  • Medicine
  • Annals of oncology : official journal of the…
  • 2005 (First Publication: 1 August 2005)
  • BACKGROUND ZD6474 selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor and epidermal growth factor receptor. The safety, tolerability and pharmacokineticsExpand